Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Genmab and Medarex announce filing of a clinical trial application for HuMax-Inflam/MDX01810 Dec 2002
Genmab, quarterly statement of shareholdings from 28 November 200228 Nov 2002
Genmab, current statement of shareholdings on 21 November 200221 Nov 2002
Genmab, Genmab’s Strategy Update13 Nov 2002
Strategy Update13 Nov 2002
Genmab, Genmab’s HuMax-CD4 to be Tested in Cancer Patients11 Nov 2002
Genmab, announces strategy update presentation6 Nov 2002
Genmab Announces Strategy Update Presentation
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
6 Nov 2002
Genmab, Genmab Announces HuMax-CD20 Program28 Oct 2002
Genmab, 3rd quarterly report 200214 Oct 2002
Genmab, Grant of Warrants in Genmab A/S26 Sept 2002
Genmab, HuMax-CD4 in Combination Therapy Not Effective in Rheumatoid Arthritis24 Sept 2002
  • Previous
  • 1
  • More pages
  • 150
  • 151
  • 152
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863